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The recent Latin American and European guidelines published this year has proposed as a goal for blood pressure
control in patients with diabetes type 2 a value similar or inferior to 140/90 mmHg. High blood pressure is the
leading cause of cardiovascular diseases and deaths globally. Although once hypertension is detected, 80% of
individuals are on a pharmacologic therapy only a minority is controlled. Diabetes also is a risk factor for other
serious chronic diseases, including cardiovascular disease. Whether specifically targeting lower fasting glucose levels
can reduce cardiovascular outcomes remains unknown. Hypertension is present in 20% to 60% of patients with
type 2 diabetes, depending on age, ethnicity, obesity, and the presence of micro or macro albuminuria. High blood
pressure substantially increases the risk of both macro and micro vascular complications, doubling the risk of
all-cause mortality and stroke, tripling the risk of coronary heart disease and significantly hastening the progression
of diabetic nephropathy, retinopathy, and neuropathy. Thus, blood pressure lowering is a major priority in preventing
cardiovascular and renal events in patients with diabetes and hypertension. During many years the BP goals
recommended in patients with diabetes were more aggressive than in patients without diabetes. As reviewed
in this article many clinical trials have demonstrated not only the lack of benefits of lowering the BP below 130/80 mmHg,
but also the J-shaped relationship in DM patients. Overall we discuss the importance of define the group of patients in
whom significant BP reduction could be particularly dangerous and, on the other hand, those with a high risk of stroke
who could benefit most from an intensive hypotensive therapy. In any case, the big challenge now is avoid the
therapeutic inertia (leaving diabetic patients with BP values of 140/90 mmHg or higher) at all costs, as this would lead
to an unacceptable toll in terms of human lives, suffering, and socioeconomic costs.
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The recent Latin American [1] and European [2] guide-
lines published this year has proposed as a goal for the
blood pressure control in patients with diabetes type 2 a
value similar or inferior to 140/90 mmHg. The American
Diabetes Association (ADA) [3] guidelines recommended
similar value for systolic blood pressures but for diastolic
blood pressure the recommended value was lower that
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article, unless otherwise stated.The important role that increased levels of blood pres-
sure have as one of the principal risk factors to myocardial
infarction (MI) [4] and stroke [5], made this mater one of
special interest that need be very well supported and
universally accepted in perspective of improve the lowers
levels of hypertensive control reported worldwide. Re-
cently, the Prospective Urban Rural Epidemiology (PURE)
study demonstrated the high prevalence of hypertension
and the very low awareness, treatment and control of
hypertension worldwide [6]. This community based study
included 153,996 adults (35–70 years) from 628 rural and
urban communities from three high- income countries
(HICs), 10 upper middle and low middle income (UMIC
and LMIC) and four low-income countries (LIC) in vari-
ous parts of the world. Hypertension was defined whenCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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average blood pressure (BP) greater than 140/90 mmHg
from two measures of resting sitting BP using an auto-
mated digital device. Overall, 40.7% of participants were
found to have hypertension, with 13.3% having a BP of
at least 160/100 mmHg and 4.4% a BP of at least
180/110 mmHg. Of those with hypertension, 46.4%
were aware of this condition, 40.6% were on pharma-
cological treatment, but only 13.1% had BP controlled
(<140/90 mmHg). Overall, 12.5% of treated hypertensive
patients received two or more BP lowering medications,
with a decreasing trend from wealthier to poorer countries
(HIC, 18.1%, UMIC 14.5%, LMIC 14.1%, LIC 1.6%; P <
0.0001). Hypertension prevalence was highest in partici-
pants with diabetes (63%), and even though awareness was
74.4%, and the percentage of those who received treatment
69.3%, the control rate was only 23.3%. So, it is crucial to
improve the control of blood pressure in a group of high
risk, as is the diabetic population.
In the present article we review the crucial role of
hypertension and diabetes in the risk of develop cardio-
vascular diseases (CVD) and the evidences that support
the decision of the Latin Americans and Europeans ex-
perts, with the aim of motivating to the health team and
the subjects affected of hypertension and diabetes to par-
ticipate actively in the challenge to pass from the guide-
lines recommendations to the clinical practice and public
health programs to improve the percentage of control of
blood pressure.
The role of hypertension in the global burden of
cardiovascular disease
Cardiovascular diseases are the major causes of mortality
and morbidity globally and affect over 50% of men and
40% of women over their lifetimes [7,8]. Although age
adjusted mortality for CVD is decreasing in developed
countries, there is a sharp rise in developing countries
[9,10]. In 1990, 5.3 million CVD deaths occurred in
developed countries, whereas there were about 9 million
deaths from CVD in developing countries [11]. In
addition, CVD in developing countries occurs at a youn-
ger age. In the same year (1990) the proportion of deaths
due to CVD in those <70 years in developed countries
was 26.5% of total deaths, while in developing countries
it was 46.7%. It was estimated that the disability adjusted
life years (DALY’s) lost in developing countries was
about three times greater than that in the developed
countries [12]. Consequently, approximately three quar-
ters of the global mortality and perhaps about 80% of the
disease burden (measured as DALY’s lost) is expected to
occur in low and middle income countries (L +MIC) by
the year 2020 [13]. These numbers have not materially
changed in the last years; Thus, in 2011 two of 3 deaths
each year are attributable to non-communicable diseases(mainly heart disease, stroke, diabetes, cancers and chro-
nic respiratory disease) with four fifths of the deaths
occurring in L +MIC, with a third occurring in people
younger than 60 years. Overall, age specific non- commu-
nicable disease deaths are two times higher in L +MIC
than in high-income countries [14-16].
High blood pressure BP is the leading cause of CVD
and deaths globally. It is associated with 7.5 million
deaths (which represents one-eighth of all deaths) per
year worldwide [7,8]. The importance of BP as a modifi-
able risk factor for CVD is well recognized and many
effective and inexpensive BP-lowering treatments are
commonly available [17,18]. Therefore, BP control and
prevention of related morbidity and mortality could be
clearly achievable. However, the awareness, treatment
and control of hypertension are low in all countries, des-
pite hypertension being an easily detectable, common
and well established risk factor for CVD. The reasons
for a persisting huge gap in awareness and treatment of
hypertension, despite the identification and control of
blood pressure being prioritized by many national and
global organizations and despite the availability of cheap
and effective medications are unclear. Use of combination
therapies, which is needed to control hypertension, is rela-
tively uncommon even in wealthier countries. Although
once hypertension is detected, 80% of individuals are on a
pharmacologic therapy only a minority is controlled [6].
This suggests the need for a more aggressive approach to
BP control (e.g. by using combination therapies). A recent
study [19] using a meticulously algorithm applied to DM2
patients was able to lower BP, however more than
half of the patients did not achieve the ADA/Joint
National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure: The Seventh
Report (JNC 7) targets demonstrating the complexity of
BP control in this population.
The BP Lowering Treatment Trialists Collaboration
(BPLTTC) meta-analysis of individual patient data from
over 160,000 participants in 29 trials showed that lower-
ing systolic BP by 5 mmHg over 4 to 5 years with most
drugs, including blockers of the renin-angiotensin- al-
dosterone system (RAAS) reduced the risk of ischemic
heart disease (IHD) by 20%, stroke by 28% and major
CVD events by 22%, with additional reductions in heart
failure [18]. Since five treatment groups (diuretics, beta
blockers, angiotensin converting enzyme inhibitors, angio-
tensin receptors blockers and calcium channel blockers)
have demonstrated not only anti-hypertensive but also
cardio-preventive efficacy, as well as renal and cerebrovas-
cular protection, all of them are of choice in patients with
hypertension and diabetes type 2 (DM2). However, when
selecting to start treatment with monotherapy, drugs that
blocking the renin-angiotensin-aldosterone system should
be primarily prescribed for its nefro-protective effect.
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ated, and this is very important issue in patients with
chronic diseases such as hypertension and DM2 where
adherence is essential. As a general rule, a long acting
drugs providing protection for 24 hours must be indicated
in order to use single doses, which offer greater protection
and improve patient adherence to treatment [20,21].
Recently, a systematic review and bayesian network meta-
analysis comparing the effectiveness of renin-angiotensin
system blockers and other antihypertensive drugs in
patients with diabetes, have concluded that the reno-pro-
tective effects and superiority of using ACE inhibitors in
patients with DM2, and also that the available evidence is
not able to show a better effect for ARBs compared with
angiotensin converting enzyme inhibitors (ACEI). Cal-
cium channel blockers might be the preferred treatment
in combination with ACEI if adequate blood pressure con-
trol cannot be achieved by ACEI alone [22].
Diabetes and cardiovascular diseases
Diabetes is a metabolic disorder that is diagnosed when
the fasting and/or post load glucose level rises above
well-established thresholds. For instance, the criteria for
diagnosis of DM2 adopted and recommended by the
Latin American Consensus [1], are listed as follows:
1. Fasting glucose at least 126 mg/dl in two successive
readings
2. At least 200 mg/dl 120 min after oral glucose
tolerance test
3. At least 200 mg/dl at any time in the presence
of symptoms
These thresholds were chosen because they identified
people at particularly high risk for retinopathy based on
epidemiological data. These data also have shown that
people with diabetes and poorly controlled glucose levels
have higher risks of retinopathy than people with dia-
betes and well-controlled glucose levels [23,24]. Diabetes
also is a risk factor for other serious chronic diseases,
including cardiovascular disease. Indeed, a recent metaa-
nalysis of large prospective studies comprising 450.000
people showed that men and women with diabetes are 2
and 3 times more likely, respectively, to die of coronary
heart disease than men and women without diabetes
[25]. Moreover, epidemiological analyses of prospective
data from the United Kingdom Prospective Diabetes
Study (UKPDS), which recruited people with newly diag-
nosed diabetes showed that progressively higher HbA1c
levels predicted higher hazards of severe retinal or renal
disease, cataracts, myocardial infarction, heart failure, am-
putation or peripheral vascular disease, stroke, and death
[26]. They also showed that the risk relationship differed
with respect to outcome, with a stronger relationship tosome outcomes and a weaker relationship to others. Thus,
organ systems may vary in their susceptibility to damage re-
lated to glucometabolic abnormalities, a proposal strongly
supported by epidemiological analysis [27].
Whether specifically targeting lower fasting glucose
levels can reduce cardiovascular outcomes remains un-
known. Some clues may reside in the 10-year-long UKPDS,
which randomized people with newly diagnosed diabetes
and few other cardiovascular risk factors to a policy of
targeting fasting plasma glucose 108 mg/dl versus a con-
ventional policy targeting fasting plasma glucose 270 mg/dl
[28,29]. This study reported a clear reduction in myocardial
infarction and death in a subset with recently diagnosis of
DM2 and obese participants allocated to metformin as the
means of glucose lowering, with no significant cardiovas-
cular effects in the other participants [29]. Moreover, after
9 years of passive follow-up, all participants experienced a
13% and 15% reduction in death and myocardial infarction,
respectively, and the subset given metformin retained the
benefit observed during the active treatment phase [30].
These results have support the proposal that the intensive
therapy to normalize blood glucose in perspective of pre-
vent CVD is effective only if is started from the very beg-
ging diagnosed of DM2 [31].
Individuals with DM2 are less likely to survive a first
myocardial infarction than their no diabetic peers. There-
fore, early identification of coronary artery disease (CAD)
in the diabetic population is needed. The mechanism of
acute coronary syndrome and their implications for therapy
haven recently reviewed [32], included the role of hypergly-
cemia [33]. However, the fact that CAD is often asymp-
tomatic in diabetic patients makes such identification a
challenge. A number of studies have shown that silent myo-
cardial ischemia as evidenced by non-invasive tests such as
the electrocardiogram stress test, myocardial scintigraphy
or stress echocardiography affects 20-50% of diabetic pa-
tients with additional risk factors [34,35]. The term of silent
ischemia includes an entity named true silent myocardial is-
chemia or clandestine ischemia, which is characterized by
myocardial perfusion defects in the absence of both angina
and ST-segment depression > 1 mm during the exercise
test. In the largest study performed to evaluate the preva-
lence of silent myocardial ischemia in diabetic patients, the
DIAD (Detection of Ischaemia in Asymptomatic Diabetics)
study [34] reported that patients with DM2 have a high
prevalence of silent myocardial ischemia and true silent
myocardial ischemia. The detection of asymptomatic CAD
was associated with a higher number of interventions, but
without a benefit in outcomes. Recently [35] it was evaluate
the prevalence of true silent myocardial ischemia in asymp-
tomatic DM2 patients in comparison with a non-diabetic
control group. Risk factors of CVD were similar between
both groups. The prevalence of true silent myocardial
ischemia was strikingly higher in DM2 than in their no
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lent myocardial ischemia, men are more likely to have per-
fusion defects. Moreover, as occurs in silent ischemia the
number of traditional risk factors is not useful as a means
of identifying patients with true silent myocardial ischemia
[36]. An important finding was that diabetes retinopathy
(DR) is independently associated with the presence of true
silent myocardial ischemia. DR has been recently recog-
nized as an indicator of risk for CAD in diabetic patients
[36] and it is predictive of cardiovascular mortality [37]. A
recent meta-analysis that have included 20 studies and
19,234 subjects have shown that DR predicts all-cause mor-
tality and CV events in both type 1 and 2 diabetic patients
[38]. These results support the concept that micro and
macrovascular complications of diabetes share common
pathogenic mechanisms beyond those related to the clas-
sical risk factors. The common pathogenic mechanisms
between micro and macrovascular complications are
uncertain but there is emerging evidence to suggest that
endothelial dysfunction, platelet dysfunction, oxidative
stress, inflammation, and advanced glycation end products
are pathogenic factors for both micro and macrovascular
complications in diabetic patients [39]. Although cost-
effectiveness studies are still needed it is undeniable
that DM2 could benefit from the identification of silent
myocardial ischemia. In the DIAD study asymptomatic
diabetic patients with moderate or large myocardial perfu-
sion defects had a 6-fold greater cardiac risk than those
with normal studies or small defects [34]. However, the
meaning of a positive SPECT in the setting of true silent
myocardial ischemia, in particular when perfusion deficits
are of mild intensity, remains to be elucidated. Meanwhile,
in terms of clinical practice it would be reasonable to be
especially rigorous in achieving a tight control of risk fac-
tors and blood glucose in these patients. In the DIAD
study, a more intensive treatment of cardiovascular risk
factors was associated with the resolution of perfusion
deficits [40]. In the study of Hernandez et al. [35], the
probability of having myocardial perfusion defects in an
asymptomatic diabetic patient with DR was 11.7 (IC95%:
3.7-37). Therefore, patients with DR are good target popu-
lation for indicating SPECT. This information is import-
ant not only for the management of diabetic patients but
also in terms of the economic burden. The current guide-
lines already identify the need for routine screening for
DR. In addition to appropriate vision care, the detection
of DR might now also warrant a fuller cardiac evaluation
and closer follow-up to prevent the development of CAD.
The goals of blood pressure in the patient with diabetes
and hypertension
Hypertension is present in 20% to 60% of patients with
type 2 diabetes, depending on age, ethnicity, obesity, and
the presence of micro or macro albuminuria [41]. HighBP substantially increases the risk of both macro and
micro vascular complications, doubling the risk of all-
cause mortality and stroke, tripling the risk of coronary
heart disease and significantly hastening the progression
of diabetic nephropathy, retinopathy, and neuropathy
[41-43]. In these patients, a difference of 5 mmHg in
either systolic blood pressure (SBP) or diastolic blood
pressure (DBP) increases the risk of cardiovascular
events or death by 20% to 30% [44]. In observational
studies, people with both diabetes and hypertension have
approximately twice the risk of cardiovascular disease as
no diabetic people with hypertension, and are also at
increased risk for diabetes specific complications, includ-
ing retinopathy and nephropathy. In the UKPDS epide-
miologic analysis, for each 10 mmHg decrease in mean
SBP the estimated risk of any complication related to
diabetes, deaths related to diabetes, MI, and micro vas-
cular complications was reduced by 12%, 15%, 11%, and
13%, respectively [45]. These results are in keeping with
the 15% risk reduction for cardiovascular death reported
in the Seven Countries Study and to the estimates of the
Multiple Risk Factor Intervention Trial (MRFIT) for
diabetic patients [46,47]. Thus, BP lowering is a major
priority in preventing cardiovascular and renal events in
patients with DM2 and hypertension.
During many years the BP goals recommended in
patients with diabetes were more aggressive than in
patients without diabetes [48-53]. Moreover, it was
proposed the maximum of “the lower the better” with
no threshold [53]. However, the 2009 European Society
of Hypertension guidelines proposed that lowering the
blood pressure to less than 130/80 mmHg in patients at
high risk for cardiovascular events was unsupported by
prospective trial data, and that the systolic blood pres-
sure should be lowered to less than 140 mmHg in these
patients [54]. Moreover, this reappraisal of the European
guidelines addressed the issue of the so- called J-curve
and the clinical implications from this phenomenon,
subject that has been reviewed recently [55-58]. The rec-
ommendations suggest lowering the SBP/DBP to values
within the 130-139/80- 85 mmHg range in all hyperten-
sive patients [54]. Several news clinical trials, including a
retrospective analysis supported this recommendation.
The International Verapamil SR- Trandolapril Study
(INVEST) [59] in which the patients were divided into
three groups depending on the achieved BP: (1) those
who had not reached the control level (SBP >140 mmHg),
(2) those who had reached the standard control level
(SBP <140-130 mmHg) and (3) those on intensive BP
control (SBP <130 mmHg). In patients with non-
controlled BP, the risk of death, MI or stroke was as
much as 50% higher compared to those with controlled
BP (HR 1.46; p < 0.0001). Interestingly, it was observed an
increased risk of death due to any cause - about 8% after
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(p = 0.06) and 1.15 (p = 0.04), respectively] in patients with
intensively controlled BP. Additional analyses revealed
that this risk was caused by a higher incidence of death in
patients with SBP below 115 mmHg [59]. The Action to
Control Cardiovascular Risk In Diabetes - Blood Pressure
Arm (ACCORD-BP) study [44] was designed to evaluate
the impact of treatment aimed at intensive lowering of
SBP to <120 mmHg (compared to standard therapy) on
the incidence of CV events in 4,733 DM patients. The
study enrolled high-risk DM patients: aged >40 and with
coexisting CVD; or aged >55 with marked atherosclerosis,
albuminuria, and LVH; or with at least two risk factors for
CVD: dyslipidemia, arterial hypertension, smoking or
obesity. After a year of treatment, the mean SBP was
119.3 mmHg in the group managed intensively and
133.5 mmHg in the group on standard therapy, while the
mean DBP values were 64.4 and 70.5 mmHg, respectively.
The primary endpoint, comprising nonfatal MI or stroke,
or death due to CV causes, occurred in 445 patients
(1.87% per year in the group on intensive treatment com-
pared with 2.09% of those on standard therapy; p = 0.20).
In addition, there were 294 deaths due to any cause
(1.28% in the intensive therapy group vs. 1.19% in the
standard treatment group; p =0.55) and 118 due to cardio-
vascular causes (0.52% vs. 0.49%, respectively; p = 0.74).
The incidence of stroke was significantly higher in the
group receiving standard treatment (0.53% vs. 0.32%;
p = 0.01); a similar relationship was found for non-fatal
stroke (0.30% vs. 0.47%; p = 0.03). It was concluded that in-
tensive hypotensive therapy did not significantly reduce the
incidence of primary endpoints or the majority of second-
ary endpoints; however, it was associated with a significant
reduction in the total number of strokes (by 41%; HR 0.59;
95% CI, 0.39-0.89; p = 0.03) and nonfatal strokes (by 37%).
In the intensive therapy group, the incidence of adverse
complications of treatment (orthostatic hypotension, hyper-
kalemia, syncope, bradycardia, arrhythmia or renal function
impairment) was significantly increased (3.3% vs. 1.3%).
Thus, the ACCORD-BP study demonstrated the import-
ance of defines the group of patients in whom significant
BP reduction could be particularly dangerous and, on the
other hand, those with a high risk of stroke who could
benefit most from an intensive hypotensive therapy. More-
over, the ACCORD-BP study confirmed that lowering SBP
to below 115 mmHg may be dangerous [44].
In the Irbesartan Diabetic Nephropathy Trial (IDNT)
[60], similar results were observed where a DBP <85 mmHg
was associated with an increase in all-cause mortality, a
significant increase in MI, but a decreased risk for stroke.
The Appropriate Blood Pressure Control in Diabetes-
Normotension (ABCD-NT) trial [61,62], a level of
SBP <130 mmHg was not associated with a benefit in
the primary outcome (renal dysfunction) or any other CVoutcome. The active group participants did benefit from a
significant reduction in stroke. This trial randomized 470
subjects with type 2 diabetes (age: 58 years; baseline BP:
155/98 mmHg) to a DBP target of either 75 mmHg or 80
to 89 mmHg. Achieved BP was 132/78 and 138/86 mmHg
in the intensive- and the less-intensive groups, respect-
ively. No significant difference in any cardiovascular end
points, rate of progression of renal disease, or retinopathy
was reported, even if a difference in overall mortality was
also evident (6% and 11% in the intensive and less-
intensive groups, respectively).
A lack of benefits of lowering the SBP level <130 mmHg
in patients with diabetes was also observed in the recent
analysis of the ONTARGET trial [63]. In this study, an
increased cardiovascular mortality was observed in the
presence of SBP lower than 125 mmHg, compared with
SBP less than 130 mmHg. These results are consistent
with the olmesartan study, wherein a SBP lower than
120 mmHg showed a J-shaped increase of cardiovascular
mortality in the olmesartan group, compared with the pla-
cebo group [64].
Vamos et al. [65] included a total of 126,092 adult
patients (age >18 years) from the United Kingdom
General Practice Research Database (UKGPRD) with a
new diagnosis of type 2 diabetes. This study demonstrated
not only the lack of benefits of lowering the SBP below
130 mmHg, but also the J-shaped relationship in DM
patients. In patients with CVD, the tight control of SBP
(<130 mmHg) and DBP (<80 mmHg) was not associated
with improved survival.
The HOT trial included a prespecified subgroup ana-
lysis in 1,501 diabetic subjects (age: 61.5 years; baseline
BP: 170/105 mmHg), randomized to three different DBP
targets: 90, 85, and 80 mmHg [66]. Achieved BP was
144/85, 141/83, and 140/81 mmHg in the three target
groups, respectively. A target of 80 mmHg significantly
reduced both major cardiovascular event rates (11.9/
1,000 person-years; RR 0.49; 95% CI, 0.29-0.81) and car-
diovascular mortality (3.7/1,000 person-years; RR 0.33;
95% CI, 0.14-0.78) compared with a target of 90 mmHg
(24.4/1,000 person-years and 11.1/1,000 person-years,
respectively).
The results of the HOT study give place a very inten-
sive discussion about the J-shaped existence [67-69]. As
was discussed by Cooper-DeHoff et al. [57] and Garcia-
Touze and Sowers [70] in recently reviews, one of the
main concerns on intensive BP lowering is the belief that
excessive reduction of BP values, particularly diastolic,
may increase the risk of MI. In diabetic patients with
hypertension, two post hoc observational analyses have
recently raised the issue of a J-curve effect [71,72]. In
the first study [71], 6,400 patients with diabetes, CAD,
and age >50 years, from the original 22,576 participants
of the INVEST trial, were divided into three different
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(from 130 mmHg to <140 mmHg), and uncontrolled
(140 mmHg or more). Primary outcome was the first
occurrence of all-cause death, nonfatal MI, or nonfatal
stroke. During 16,893 patient-years of follow-up, 286
patients (12.7%) with tight BP control, 249 (12.6%) with
usual control, and 431 (19.8%) with uncontrolled SBP
experienced a primary outcome event. Although usual
BP control allowed a significant reduction in the cardio-
vascular event rate, as compared with the uncontrolled
group (12.6% vs. 19.8%; adjusted hazard ratio [HR], 1.46;
95% CI, 1.25-1.71; P < 0.001), little difference existed
between those with usual control and those with tight
control (12.6% vs. 12.7%; adjusted HR, 1.11; 95% CI,
0.93-1.32; P = 0.24). In addition, all-cause mortality rate
showed a no statistically significant trend toward a
higher risk in the tight-control group, as compared with
the usual control group (11% vs. 10.2%; P = 0.06), that be-
came statistically significant when the extended follow-up
was included (22.8 vs. 21.8%; P = 0.04). A major limitation
of the latter finding was the fact that no BP data were col-
lected during the extended follow-up [73].
In the second study, a post hoc observational analysis
on the diabetic patients of the UKPDS [72] investigators
randomly assigned patients with diabetes to either ‘tight
BP control’ (<150/85 mmHg) or ‘less-tight BP control’
(<180/105 mmHg). Patients in the <150/85 mmHg
group had a mean baseline BP of 159/94 mmHg and
achieved a mean BP of 144/82 mmHg, whereas those in
the <180/105 mmHg group had a mean baseline BP of
160/94 mmHg and achieved a mean BP of 154/87 mmHg
after more than 8 years of follow- up. Compared with
the less-tight-control group, those in the tight-control
group had a significant 44% reduction in risk of stroke
(P = 0.013), a 32% reduction in risk of diabetes- related
death (P = 0.019), and a 24% reduction in risk of
diabetes-related end points (P = 0.0046). When the UKPDS
investigators performed an additional 10-year follow-up of
the patients [73], which included in-person visits and ques-
tionnaires but no attempt to intervene on BP, the benefits
observed in the tight-control group at the first 8-year
follow-up were no longer present. Over the entire 20-year
follow-up period, no difference in the rate of any
diabetes-related end points, MI, microvascular disease,
or all-cause mortality was observed between the tight-
control and less-tight-control groups [73]. The Table 1
summarizes the main results of the clinical trials
about discussed.
We refer the above-cited reviews [56,57,70] for the
explanation of the pathophysiologic interpretation of the
J-curve that lies in the mechanisms of coronary artery
perfusion, which depends on the pressure gradient between
the coronary arteries and the left ventricle during the dia-
stolic phase of the cardiac cycle. However, the concept of aJ-curve has been challenged by several observational stud-
ies and randomized controlled trials, in which the J-curve
effect was not clearly evident. In addition, other explana-
tions about the finding of a J-curve have been proposed; in
particular, reverse causality views coexisting in chronic dis-
eases or poor health conditions as a cause for concomitant
low DBP, which could lead to a spurious association with
increased morbidity and mortality.
Chronic kidney disease (CKD), defined by a reduced
glomerular filtration rate (GFR) is common in subjects
with DM2 and hypertension [74,75]. Nowadays CKD is
affecting 10-15% of the adult general population and it is
associated with an increased risk of CVD [76]. Guide-
lines recommended lower BP targets in this population
than in people without CKD [77]. Moreover, it has been
suggested that the inhibitors of the RAAS have particu-
lar benefits for the prevention of renal complication
[78]. A recent meta-analysis of randomized controlled
trials [79] that included 25 trials and 152,290 individuals
showed that BP lowering regimens in relation to placebo
reduced the risk of mayor CV events in individuals with
and without reduced GFR with no evidence for any dif-
ference in effect. The results were similar irrespective of
whether BP was reduced by regimens based on different
antihypertensive drugs. This meta-analysis provides clean
evidence that a broad range of different BP lowering regi-
ments provide protection against CVD in patient with
CKD. However, the results of the ONTARGET trial [21]
and of the VA NEPHRON study [80] have clearly demon-
strated that the combination of an ACEI plus an ARB not
is recommend because of the increased risk of adverse
events among patients with diabetic nephropathy. More-
over, as revised by Wu et al. [22], two large scale placebo
controlled trials for diabetic nephropathy using the ARBs
Irbesartan and Olmesartan [81,82] have shown a higher
rate of CV death among patients randomized to the ARB
group. On the other hand, the ONTARGET trial [21,83]
using the ARB Telmisartan and the ACEI ramipril, showed
equivalent cardioprotective effects of both RAAS blockers
in patients with high risk of CVD or DM2. Nevertheless,
participants in this trial were not randomized based on the
presence of DM2 or the severity of nephropathy. The
meta-analysis of Wu [22] concludes that since there is no
evidence to show a better protective effect for ARBs
compared with ACEI, the use of ACEI is recommended
when cost is a concern.
Conclusions
The importance of BP as a modifiable risk factor for
CVD, especially in patients with diabetes is well recog-
nized, and many effective and inexpensive BP-lowering
treatments are commonly available. The recent Latin
American (1) and European (2) guidelines, published this
year has recommended as a goal for the blood pressure
Table 1 Studies addressing the definition of the goal of blood pressure control in patients with diabetes and hypertension
Study Ref Number of
subjects





INVEST 58 6,400 Observational
subgroup analysis
Group 1. SBP<140 Group 1. 159/86 Group 1 have 50% higher risk of death,
MI, or stroke (P< 0.0001). Group 3 in
relation to group 2 have an increase of
8% of CVD after 5 years of study (p<0.04).
Group 2. SBP<140-130 Group 2. 149/85
Higher incidence of death in patients
with SBP<115.
Group 3. SBP<130 Group 3. 144/85




Group 1. 119.3/64.4 No differences in the primary end point
(MI, stroke and CV death) or in death
due to any cause. Higher incidence of
stroke (p= 0.01) or non-fatal stroke





IDN-T 59 1,590 Post hoc analysis ≤135/85 30% reach the SBP goal
and 81% the DBP goal
Progressively lower achieved SBP to 120
predicted a decrease in CV mortality and
CHF but not MI. A SBP <120 was
associated with increased CV deaths and
CHF events. DBP< 85 was associated with
increase of all-cause mortality, MI
mortality but decrease risk of stroke.
ABCD-NT 60,61 470 RCT Group 1. DBP<75-79 132/78 No differences in any CV events, or
progression of renal disease, nor
retinopathy.Group 2. DBP 80-89 138/86
ONTARGET 62 9,603 Post hoc analysis Group 1. SBP 95-130 125.8 SD 12.0 Increased CV mortality with SBP < 125 in
relation with SBP < 130.
Group 2. SBP 131-142 132.4 SD 11.2
Group 3. SBP 143-154 137.7 SD 11.5
Group 4. SBP 155-200 144.3 SD 12.6
ROADMAP 63 4,447 RCT Group 1. SBP<130 80% achieved
the target
SBP<120 showed a J-shaped increase of
CV mortality.
Group 2. DBP<80
UKGPRD 64 126,092 Retrospective study Group 1. <130/<80 Achieved target J-shaped relationship in patients with
SBP<130 In patients with CVD SBP <130
and DBP< 80 was not associated with
improved survival. BP <110/75 increase
the risk of CV mortality.
12,379
with CVD
Group 2. 130-139/80-<85 Group 1. SBP18.1%
Group 3. ≥140/≥85 DBP 35.7%
Group 2. SBP 19.9%
DBP 27.7%
Group 3. SBP 61%
DBP 36.6%
HOT 65 1,501 RCT Group 1. DBP<90 Group 1. 144/85 DBP<80 showed a significantly reduction
in CV events and CV mortality.
Group 2. DBP<85 Group2. 141/83
Group 3. DBP<80 Group 3. 140/81
UKPDS 71 4,801 Post hoc
observational
analysis
Group 1. <150/85 Group 1. 144/82 Group 1 had a significant 44% reduction
of stroke, 32% of diabetes related death,
24% diabetes related end patients.Group 2. <180/105 Group 2. 154/87
BP= blood pressure, SBP=systolic BP, DBP= diastolic BP, MI=myocardial infarction, CVD= cardiovascular diseases CV=cardiovascular, CHF= congestive heart failure.
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or inferior to 140/90 mmHg. Therefore, BP control and
prevention of related morbidity and mortality is clearly
achievable. However, the awareness, treatment and control
of hypertension are low worldwide. The big challenge now
is avoid the therapeutic inertia (leaving diabetic patients
with BP values of 140/90 mmHg or higher) at all costs, as
this would lead to an unacceptable toll in terms of humanlives, suffering, and socioeconomic costs. The health team
and the subjects affected of hypertension and diabetes
must to participate actively in the challenge to pass from
the guidelines recommendations to the clinical practice
and public health programs, to improve the percentage of
control of high BP. Moreover, the development of re-
search aimed to evaluate new approaches to effectively
diagnostic, treated and control high BP is a priority [84].
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